| 0.65 -0.022 (-3.25%) | 07-31 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.8  |
1-year : | 0.85 |
| Resists | First : | 0.69 |
Second : | 0.73 |
| Pivot price | 0.69 |
|||
| Supports | First : | 0.62 | Second : | 0.52 |
| MAs | MA(5) : | 0.67 |
MA(20) : | 0.69 |
| MA(100) : | 1.08 |
MA(250) : | 1.67 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1  |
| %K %D | K(14,3) : | 11.9 |
D(3) : | 24 |
| RSI | RSI(14): 30.7 |
|||
| 52-week | High : | 2.93 | Low : | 0.62 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NSPR ] has closed below the lower bollinger band by 6.6%. Bollinger Bands are 72.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 23 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.68 - 0.68 | 0.68 - 0.69 |
| Low: | 0.64 - 0.64 | 0.64 - 0.65 |
| Close: | 0.64 - 0.65 | 0.65 - 0.66 |
InspireMD, Inc., an Israel-based medical technology company established in 2005, specializes in creating and commercializing advanced medical devices. Its core expertise lies in the proprietary MicroNet stent platform technology, engineered to address various vascular and coronary diseases. The company's offerings, distributed through a network of local partners, reach markets across Europe, Latin America, the Middle East, and Asia Pacific. Key products include the CGuard carotid embolic prevention system, specifically designed for carotid artery procedures, and the MGuard Prime embolic protection systems. The MGuard Prime systems are crucial for patients experiencing acute coronary syndromes, notably acute myocardial infarction, and those undergoing saphenous vein graft coronary interventions or bypass surgery. InspireMD is also developing PVGuard, an innovative solution combining a MicroNet mesh sleeve with a self-expandable stent, aimed at peripheral vascular applications.
Thu, 30 Jul 2026
Medical-device sales leader with more than 30 years returns to InspireMD - Stock Titan
Thu, 30 Jul 2026
InspireMD Inc (NSPR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Thu, 30 Jul 2026
InspireMD Inc (NSPR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Thu, 30 Jul 2026
InspireMD Inc (NSPR) Institutional Confidence - TradingKey
Wed, 29 Jul 2026
InspireMD, Inc. (NASDAQ: NSPR) eliminates chief commercial officer position - Stock Titan
Mon, 27 Jul 2026
InspireMD Inc (NSPR) Income Statement - TradingKey
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 47 (M) |
| Shares Float | 26 (M) |
| Held by Insiders | 19.8 (%) |
| Held by Institutions | 48.6 (%) |
| Shares Short | 77 (K) |
| Shares Short P.Month | 53 (K) |
| EPS | -0.7 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.93 |
| Profit Margin | 0 % |
| Operating Margin | -411.4 % |
| Return on Assets (ttm) | -68.5 % |
| Return on Equity (ttm) | -142.7 % |
| Qtrly Rev. Growth | 122.1 % |
| Gross Profit (p.s.) | 0.06 |
| Sales Per Share | 0.23 |
| EBITDA (p.s.) | -1.11 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -39 (M) |
| Levered Free Cash Flow | -21 (M) |
| PE Ratio | -0.93 |
| PEG Ratio | 0 |
| Price to Book value | 0.69 |
| Price to Sales | 2.8 |
| Price to Cash Flow | -0.79 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|